10 patients have been treated to date with azer-cel in the Phase 1b diffuse large B-cell lymphoma (DLBCL) trial Cohort A: 6 patients were treated with azer-cel and lymphodepletion (chemotherapy) 1 ...

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase ...

- Precision to Receive $17.5 Million in Upfront and Near-Term Payments with Potential for up to $288 Million in Other Development Milestone Payments - Upfront Cash and Near-Term Payments Expected to ...

Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and ...

TG Therapeutics, Inc. (NASDAQ:TGTX) has been doing quite well, continuing to grow its revenue with respect to its FDA-approved drug BRIUMVI (ublituximab) for the treatment of patients with relapsing ...

SYDNEY, July 14, 2025 /PRNewswire/ -- Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce exciting new data from its Phase 1b clinical trial evaluating ...